BioSpace News Archive

Genetown

iSpecimen Launches Marketplace Onsite Program to Optimize Biospecimen Procurement Process for Sample ProvidersNew Program Designed to Support Provider Partners with Onsite Coordinator

iSpecimen Inc. today launched its new Marketplace Onsite program to offer additional support to the Company’s biospecimen provider partners.

October 4, 2022
·
4 min read
Drug Development

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic epidermolysis bullosa (RDEB).

October 4, 2022
·
4 min read
Drug Development

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

Mind Medicine today announced the initiation of a Phase 1 investigator-initiated trial led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB).

October 4, 2022
·
5 min read
Pharm Country

Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients

Biohaven Ltd. (NYSE: BHVN) launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases.

October 4, 2022
·
10 min read
Biotech Beach

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed.

October 4, 2022
·
5 min read
Policy

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

Immutep Limited announced the United States Food and Drug Administration has granted Fast Track designation to eftilagimod alpha in combination with pembrolizumab for the treatment of 1st line non-small cell lung cancer.

October 4, 2022
·
4 min read
Genetown

Merck KGaA, Darmstadt, Germany, Partners with CNote to Invest $20 Million in Under-resourced Communities

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced it made a $ 20 million commitment to CNote, a women-led impact investment platform.

October 4, 2022
·
3 min read
BioMidwest

Esaote North America Ultrasound division awarded contract with Vizient, Inc.

Esaote North America announces a multi-year contract with Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company, serving more than 50% of the nation’s acute care providers.

October 4, 2022
·
1 min read
Drug Development

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

Exelixis, Inc. announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial, which is evaluating XL092 in combination with multiple immune checkpoint inhibitors in advanced solid tumors.

October 4, 2022
·
6 min read
Drug Development

Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia

Abcuro, Inc. announced initiation of a Phase 1/2 dose escalation trial to evaluate the safety, tolerability, and proof-of-concept of ABC008 in patients with T cell large granular lymphocytic leukemia who suffer from anemia and/or neutropenia.

October 4, 2022
·
2 min read